J B Chemicals & Pharmaceuticals receives supplementary ANDA approval for Atenolol Tablets

From USFDA

J B Chemicals & Pharmaceuticals announced that the USFDA has approved the Company's supplementary Abbreviated New Drug Application (sANDA) for Atenolol Tablets USP 25 mg, 50 mg and 100 mg (anti-hypertensive) manufactured using Company's own bulk drug (API). The Company had initiated this change as a part of its plant to gradually backward integrate US formulations business. This approval is expected to boost Company's US sales.

Powered by Capital Market - Live News